Ifosfamide in the treatment of soft tissue sarcomas.
Elizabeth Connelly, G. Thomas Budd
Abstract
Elizabeth Connelly, G. Thomas Budd
Abstract
Ifosfamide is one of the three most active agents in the treatment of soft tissue sarcomas. Ifosfamide-induced urothelial toxicity has been adequately controlled with the use of hydration and the uroprotective agent mesna. This is a review of pilot and phase I and II studies of ifosfamide as a single agent and randomized trials of combination chemotherapy regimens incorporating ifosfamide in the treatment of soft tissue sarcomas. Issues of schedule and dose of ifosfamide will be addressed as well.
OpenAlex reports 18 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Ifosfamide is one of the three most active agents in the treatment of soft tissue sarcomas. Ifosfamide-induced urothelial toxicity has been adequately controlled with the use of hydration and the uroprotective agent mesna. This is a review of pilot and phase I and II studies of ifosfamide as a single agent and randomized trials of combination chemotherapy regimens incorporating ifosfamide in the treatment of soft tissue sarcomas. Issues of schedule and dose of ifosfamide will be addressed as well.
Key concepts: Ifosfamide, Mesna, Medicine, Chemotherapy, Soft tissue, Nitrogen mustard, Soft tissue sarcoma, Sarcoma